Member Info for JustJimmy

If you have no market confidence, you’ve got big problems....even when listing onto the NASDAQ............... a successful phase 3 will sort that.

"Why Are they selling? Just before SITC? With trials going very well and Keytuda achieving 13b USD yearly in sale?????" ............ presumably they've made their margin and/or are looking to fund some other investment. For % hunters there's plenty time to hop in and out ........... they could buy back in after we multi-bag if they reckon there's further gains.

Realistically........... 5/10% within a few months is a marvellous ROI for large investors.

There has been plenty of good news recently.......... I imagine a re rate is inevitable but markets and especially AIM is less than rationale. The NASDAQ news is the key to the real value of this being realised.

This "wrong again" thing is daft as fnck ........... anyone who invests based on Zengahs utterings deserve to lose their arse IMO ..................

Deal is agreed, £1.10 is the price

The market isn't overly inspired.......... loony at this stage.......... we should be well over £2

Surely news is inevitable with the presentations?

It looks like the money shall come after the next RNS and not before........ as an investor in this for the longterm I can live with that to be honest. At current SP this can't be considered as anything but hugely discounted I believe.

It looks like the money shall come after the next RNS and not before........ as an investor in this for the longterm I can live with that to be honest. At current SP this can't be considered as anything but hugely discounted I believe.

£3.50 next week would be wonderful IMO, I don't see it happening though as there's not much rising going on with the SP this week and it's well knows about the posters/presentations next week.

Here she is.....

Virtual KOL Event SITC Data
Thu, 5th Nov 2020 12:00

RNS Number : 3781E
4d Pharma PLC
05 November 2020

4D Pharma to Host Virtual KOL Event Reviewing New Data Presented at the Society for Immunotherapy of Cancer Annual Meeting 2020 from Live Biotherapeutic MRx0518 Clinical Programs

Leeds, UK, November 5, 2020, - 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces that it will host a virtual Key Opinion Leader (KOL) event to review data presented from two ongoing clinical trials of MRx0518, the Company's lead immuno-oncology single strain Live Biotherapeutic, as both a neoadjuvant monotherapy and combination therapy in patients refractory to checkpoint inhibitors at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2020. The event will take place on Wednesday, November 11, 2020 at 1:00pm GMT (8:00am ET).

The event will feature presentations from 4D pharma management and KOLs, Dr Mark P Lythgoe, Academic Clinical Fellow in Medical Oncology and Pharmacist at Imperial College London, and Dr Shubham Pant, Associate Professor Department of Investigational Cancer Therapeutics and Department of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center.

A live webcast of the event will be available on the Reports and Presentations section of the 4D Pharma website at www.4dpharmaplc.com. To access the call, please dial 1-877-270-2148 (United States) or 1-412-902-6510 (international) and reference the 4D pharma conference call to join. A replay of the webcast and accompanying slides will be available on the 4D pharma website following the event.

8% up today as we approach three presentations at The Society for Immunotherapy of Cancer (SITC) Annual Meeting 2020 !!!!!!!!!!!!!

.......... a couple of years away from oncology product approval, as there is an option for accelerated approval

"stock market soaring" ????????????.......... FTSE100 was at 6 month low last Friday and isn't much higher today !!!!!!!!!!!

Zengah....
'Prescription drugs are where the money is' ........
Time will tell, that's my view, no need for your derogatory snipes.

Prescription drugs are where the money is ........ probiotic supplement wouldn't bring in the same revenue. As the company are confident of success the supplement route wouldn't serve much purpose and likely wouldn't drag SP too high.

I'd expect SP to rise up to mid Nov..... Shorting at 1.10 ish seems daft......

"no serious LTH would sell today" .......... indeed, can't imagine anyone needing cash now who didn't need it a few days ago.

Loads of folk in AIM stocks seem to be Ladbrokes style "investors"

............ RNS could land anyday here.

............ the SP will be back to Friday's price before too long.